Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Molecular Test Effectively Guides Extent of Initial Thyroidectomy

By LabMedica International staff writers
Posted on 05 Aug 2014
The routine use of a molecular testing panel increases the likelihood of performing the correct initial surgery for patients with thyroid nodules and cancer.

A clinical algorithm using routine cytological molecular testing (MT) promotes initial total thyroidectomy (TT) for clinically significant thyroid cancer (sTC) and/or correctly limits surgery to lobectomy when appropriate. More...
Either TT or lobectomy is often needed to diagnose differentiated thyroid cancer and determining the correct extent of initial thyroidectomy is challenging.

Scientists at the University of Pittsburgh Medical Center (Pittsburgh, PA, USA) conducted a single-institution cohort study of 671 patients with nonmalignant cytology who had thyroidectomy between October 2010 and March 2012. Cytological diagnosis was made using the 2008 Bethesda criteria, and one or more indications for thyroidectomy. The patients who received biopsies all had suspicious thyroid nodes.

Approximately half the biopsy samples were run through the molecular panel, and the other half were not. Patients whose tissue samples were not tested with the panel had a 2.5-fold higher statistically significant likelihood of having an initial lobectomy and then requiring a second operation. Using a routine algorithm for prospective MT, the team demonstrated that the likelihood of optimal initial thyroid surgery is increased by the reflexive use of testing a molecular marker panel of proto-oncogene B-Raf (BRAF), Rat sarcoma (RAS), Paired box gene 8- peroxisome proliferator-activated receptor γ 1 (PAX8-PPARγ), and Rearranged in Transformation/Papillary Thyroid Carcinomas (RET-PTC) on fine needle aspiration biopsy (FNAB) specimens.

By analyzing new data from a single institution that has been prospectively and routinely using FNAB-MT since 2007, the investigators observed that, overall, FNAB-MT facilitated a 30% increase in the appropriate use of initial TT for sTC histology and a 33% increase in the appropriate use of initial lobectomy for non-sTC histology. Yuri Nikiforov, MD, PhD, a professor of pathology and coauthor of the study said, “We're currently refining the panel by adding tests for more genetic mutations, thereby making it even more accurate. Thyroid cancer is usually very curable, and we are getting closer to quickly and efficiently identifying and treating all cases of thyroid cancer.” The study was published in July 2014 issue of the Annals of Surgery.

Related Links:

University of Pittsburgh Medical Center



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.